Slide 1: Q1 2024 Results
Q1 2024 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO April 26, 2024
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q1 2024 Financial Highlights
Q1 2024 Financial Highlights Highlights: +6% Reported Sales Growth +5% Core Sales Growth* • Off to a great start for the year • Strong demand for Pharma's proprietary drug delivery systems and improved performance of the injectables unit • Recovery in certain North American consumer end- +50% Report
Slide 4: Sustainability Recognition
Sustainability Recognition Barron’s CDP Capital Newsweek Forbes EcoVadis 3BL Media ISS ESG USA Today Le Point In the Top 100 Recognized as a France In the Top 100 One of the Sustainability Rating One of the Achieved One of the Top One of the Most Most Sustainable Supplier Named a America’s Most Worl
Slide 5: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Beauty Aptar Closures • Our Airless+ CS system is the drug delivery • Coty’s new Marc Jacobs® Daisy Wild • Aptar’s sports cap is the dispensing solution solution used to treat rosacea, recently fragrance features our pump, custom for
Slide 6: First Quarter 2024 Reported Results
First Quarter 2024 Reported Results Q1 Reported Sales Q1 Reported EPS Q1 Highlights (in millions $) $1,200 $1.40 $915 $1.23 • Aptar Pharma's strong performance was driven by $1,000 $860 6% $1.20 50% continued growth for proprietary drug delivery $800 $1.00 systems used for emergency medicine, allerg
Slide 7: First Quarter 2024 Adj. EPS and Adj. EBITDA
First Quarter 2024 Adj. EPS and Adj. EBITDA Q1 Adjusted EPS Q1 Adjusted EBITDA* (in millions $) $1.40 $200 $179 $1.26 $1.20 31% $180 $154 16% $160 $0.96 $1.00 $140 $120 $0.80 $100 $0.60 $80 $0.40 $60 $40 $0.20 $20 $- $- Q1 2023 Q1 2024 Q1 2023 Q1 2024 25.6% 20.6% Adjustments: • 2023: Restructuring I
Slide 8: Outlook
Outlook Outlook Highlights • The year is off to a great start and we will continue to Earnings Per Share build on this momentum in the second quarter $1.40 $1.30 – $1.38 • Anticipate demand for our proprietary drug delivery $1.20 $1.24 $1.22 22-24% systems and elastomeric components for biologics to
Slide 9: Appendix
Aptar4 Appendix
Slide 10: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 10
Slide 11: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 11
Slide 12: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 12
Slide 13: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 13
Slide 14: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 14
Slide 15: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 15
Slide 16: Stockholders' Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 17
Slide 18: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 18
Slide 19: Supplemental Information
Supplemental Information 19
Slide 20: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 20